SEC Company Response from Jazz Pharmaceuticals plc (JAZZ) (CIK 0001232524) (JAZZ) — Jan 17, 2020
Jazz Pharmaceuticals plc (JAZZ) (CIK 0001232524)
Date: Jan. 17, 2020 · CIK: 0001232524 · Accession: 0001193125-20-009785
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-33500
Referenced dates: November 5, 2019
Letter
Via EDGAR Division of Corporate Finance Office of Life Sciences Form 10-K for the Fiscal Year Ended December 31, 2018 Filed February 26, 2019 Form 8-K dated August 6, 2019 File No. 001-33500
Dear Ms. Mast and Ms. Connell:
On behalf of Jazz Pharmaceuticals plc (the “Company”), this letter is being transmitted to inform the staff of the Securities and Exchange Commission (the “Staff”) that the Company intends to respond to the Staff’s letter dated November 5, 2019 and subsequent oral comments regarding the Staff’s review of the above-referenced filings no later than February 3, 2020.
Please do not hesitate to contact me at +353 1 634 7818 if you have any questions or would like additional information regarding this matter.
Sincerely,
/s/ Patricia Carr
Show Raw Text
CORRESP 1 filename1.htm CORRESP www.jazzpharmaceuticals.com January 17, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Mary Mast and Angela Connell Re: Jazz Pharmaceuticals plc Form 10-K for the Fiscal Year Ended December 31, 2018 Filed February 26, 2019 Form 8-K dated August 6, 2019 File No. 001-33500 Dear Ms. Mast and Ms. Connell: On behalf of Jazz Pharmaceuticals plc (the “Company”), this letter is being transmitted to inform the staff of the Securities and Exchange Commission (the “Staff”) that the Company intends to respond to the Staff’s letter dated November 5, 2019 and subsequent oral comments regarding the Staff’s review of the above-referenced filings no later than February 3, 2020. Please do not hesitate to contact me at +353 1 634 7818 if you have any questions or would like additional information regarding this matter. Sincerely, /s/ Patricia Carr Patricia Carr Vice President, Finance and Principal Accounting Officer Jazz Pharmaceuticals plc cc: Bruce C. Cozadd, Chairman, Chief Executive Officer and Interim Principal Financial Officer Neena Patil, Senior Vice President and General Counsel Emer McGrath, KPMG Chadwick Mills, Cooley LLP Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland p 353.1.634.7800 f 353.1.634.7850 Jazz Pharmaceuticals plc. Registered in Ireland (company number 399192). Registered Office: Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland. Directors: Bruce C. Cozadd – Chairman (USA), Paul L. Berns (USA), Patrick G. Enright (USA), Peter Gray, Heather Ann McSharry, Seamus Mulligan, Kenneth W. O’Keefe (USA), Anne O’Riordan (HK), Norbert G. Riedel, Ph.D (USA), Elmar Schnee (CH), Catherine A. Sohn (USA), Rick E Winningham (USA)